Full Press Release Details
Protalix BioTherapeutics to Present at to Present at Oppenheimer Annual Healthcare Conference and
at Barclays Capital Small Mid-Cap Health Care Conference
CARMIEL, Israel, October 28, 2008 (Business Wire) Protalix BioTherapeutics, Inc. (Amex: PLX),
announced today that Dr. David Aviezer, President and Chief Executive Officer, will present at the
19th Annual Oppenheimer Healthcare Conference on Monday, November 3, 2008, at 4:00 PM EDT. The
conference is being held at the Waldorf Astoria Hotel in New York City.
Dr. David Aviezer will also be presenting at the Barclays Capital Small Mid-Cap Healthcare
Conference on Thursday, November 6, 2008, at 9:30 AM EDT. The conference is being held at the US
headquarters of Barclays Capital in New York City.
Audio webcasts of the corporate presentations will be available on the Company s website at
www.protalix.com under the events calendar section.
About Protalix BioTherapeutics
Protalix is a biopharmaceutical company. Its goal is to become a fully integrated
biopharmaceutical company focused on the development and commercialization of proprietary
recombinant therapeutic proteins to be expressed through its proprietary plant cell based
expression system. Protalix s ProCellEx presents a proprietary method for the expression of
recombinant proteins that Protalix believes is safe and scalable and will allow for the
cost-effective, industrial-scale production of recombinant therapeutic proteins. Protalix is
enrolling and treating patients in its pivotal phase III clinical trial in Israel, Europe the
United States and other locations for its lead product candidate, prGCD, for its enzyme replacement
therapy for Gaucher disease, a lysosomal storage disorder in humans, and has reached an agreement
with the United States Food and Drug Administration on the final design of the pivotal phase III
clinical trial through the FDA s Special Protocol Assessment (SPA) process. Protalix is also
advancing additional recombinant biopharmaceutical drug development programs.
The Trout Group, LLC
Marcy Strickler, 646-378-2927